RT Journal Article
T1 Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations
A1 Conway, Brian
A1 Rodriguez-Tajes, Sergio
A1 Garcia-Retortillo, Montserrat
A1 Perez-Hernandez, Paco
A1 Teti, Elisabetta
A1 Ryan, Pablo
A1 Fraser, Chris
A1 Macedo, Guilherme
A1 Morano Amado, Luis Enrique
A1 de Ledinghen, Victor
A1 Fenech, Mary
A1 Martins, Alexandra
A1 Fernanda Guerra-Veloz, Maria
A1 Ntalla, Ioanna
A1 Ramroth, Heribert
A1 Vanstraelen, Kim
A1 Hernandez, Candido
A1 Mertens, Michael
A1 O'Loan, Joss
K1 HCV elimination
K1 HCV
K1 homeless
K1 real-world
K1 sofosbuvir
K1 velpatasvir
K1 sustained virological response
K1 Hcv
K1 Care
K1 Velpatasvir
K1 Sofosbuvir
K1 People
K1 Prevalence
K1 Linkage
K1 Hiv
AB Lay abstract Reducing the prevalence of HCV in people experiencing homelessness is an important step toward elimination of viral hepatitis as a major public health threat. However, several patient and social factors can complicate treatment. Increasing treatment access and cure rates in this population requires treatment regimens to be simple, effective and well tolerated. In this real-world analysis of data collected from 15 clinical cohorts, a once daily 12-week regimen of sofosbuvir/velpatasvir, requiring minimal monitoring, achieved high cure rates across a broad range of HCV-infected people experiencing homelessness.Background: People experiencing homelessness are disproportionately affected by hepatitis C virus (HCV) and can face specific barriers to care. Simple treatment algorithms could increase linkage to care in this population. Methods: This retrospective real-world analysis pooling data from 15 clinical cohorts evaluated effectiveness of a once-daily sofosbuvir/velpatasvir (SOF/VEL) regimen in HCV-infected people experiencing homelessness. The primary outcome was sustained virological response (SVR) in the effectiveness population (patients with confirmed SVR status). Secondary outcomes included reasons for not achieving SVR, adherence and time between diagnosis and SOF/VEL treatment start. Results: Of 153 patients treated with SOF/VEL for 12 weeks without ribavirin, SVR was 100% in the effectiveness population (n = 122), irrespective of various baseline factors including active injecting drug use and presence of mental health disorders. Conclusion: HCV-infected people experiencing homelessness can successfully be treated with SOF/VEL. SOF/VEL enables implementation of simple treatment algorithms and can support test-and-treat strategies through rapid treatment starts and minimal monitoring.
PB Future medicine ltd
SN 1746-0794
YR 2021
FD 2021-12-17
LK http://hdl.handle.net/10668/20497
UL http://hdl.handle.net/10668/20497
LA en
DS RISalud
RD Jul 17, 2025